Stock Comparison

ABBV vs NVO

AbbVie Inc vs Novo Nordisk A/S

The Verdict

NVO takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

NVO

Novo Nordisk A/S

1.3

out of 10

Distressed

Head-to-Head

$381.1B

Market Cap

$1.3T

104.8

P/E Ratio

10.6

5.8%

Profit Margin

37.2%

95.6%

Return on Equity

66.4%

20.2

Debt-to-Equity

0.7

Moderate

Overall Risk

Moderate

0.1

DVR Score

1.3

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

NVO1.3/10

Novo Nordisk (NVO) is a pharmaceutical powerhouse, commanding leadership in the diabetes and obesity markets, fueled by its dominant GLP-1 franchise. The Q1 2026 results show strong reported sales growth of 32% YoY at CER, and the company raised its 2026 outlook, reflecting robust demand. However, a critical red flag for 10x growth potential is the explicit *4% decline in adjusted sales due to low...

Full NVO Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.